Cited by 3,481Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Open access

Gibb, W R, Lees, A J·1988·Journal of Neurology, Neurosurgery & Psychiatry

DOI 10.1136/jnnp.51.6.745PMC PMC1033142

Open this paper in CoChat — free account Open PDF

Abstract

The Lewy body is a distinctive neuronal inclusion that is always found in the substantia nigra and other specific brain regions in Parkinson's disease. It is mainly composed of structurally altered neurofilament, and occurs wherever there is excessive loss of neurons. It occurs in some elderly individuals and rarely in other degenerative diseases of the central nervous system. In 273 brains of patients dying from disorders other than Parkinson's disease, the age-specific prevalence of Lewy bodies increased from 3.8% to 12.8% between the sixth and ninth decades. Associated pathological findings suggest that these cases of incidental Lewy body disease are presymptomatic cases of Parkinson's disease, and confirm the importance of age (time) in the evolution of the disease. In view of the common and widespread occurrence of this disorder we propose that endogenous mechanisms operating in early life may be more important than environmental agents in the pathogenesis of Lewy bodies and Parkinson's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/jnnp.51.6.745

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Basal forebrain neurons in the dementia of Parkinson disease
Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 535
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & Langston, J. W. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?
Kosaka, K., Yoshimura, M., Ikeda, K., & Budka, H. (1984) · PubMed · Cited by 401
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys
Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I., & Ricaurte, G. A. (1986) · Annals of Neurology · doi:10.1002/ana.410200403 · Cited by 351
Parkinson's disease in 65 pairs of twins and in a set of quadruplets
Ward, C. D., Duvoisin, R. C., Ince, S. E., Nutt, J., Eldridge, R., & Calne, D. B. (1983) · Neurology · doi:10.1212/wnl.33.7.815 · Cited by 347
PHASE AND ELECTRON MICROSCOPIC OBSERVATIONS OF LEWY BODIES AND MELANIN GRANULES IN THE SUBSTANTIA NIGRA AND LOCUS CAERULEUS IN PARKINSONʼS DISEASE
Duffy, P. E., & Tennyson, V. M. (1965) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196507000-00003 · Cited by 345
THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE
Gibb, W. R. G., & Lees, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 325
Self-citation
Esophageal Lewy bodies associated with ganglion cell loss in achalasia
Qualman, S. J., Haupt, H. M., Yang, P. H., & Hamilton, S. R. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90079-9 · Cited by 305
Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease.
Qualman, S. J., Haupt, H. M., Yang, P. H., & Hamilton, S. R. (1984) · PubMed · Cited by 295

Show all 39 references

Research works printed but not linked: 7

Gibb WRG. The Lewy body and Parkinson's disease. In: Clifford Rose F, ed. Parkinson's Disease: Clinical and Experimental Advances. London: John Libbey and Co, 1987:3-11.
Oppenheimer D. Neuropathology of progressive autonomic failure. In: Bannister R, ed. Autonomic failure. Oxford University Press, London, 1983:267-83.
Sigwald J, Lapresle J, Raverdy P, Recondo NJ. Atrophie cerebelleuse familiale avec association de lesions nigeriennes et spinales. Presse Med 1964;72:557-62.
Vogt C, Vogt 0. Erkrankungen der GroBhirnrinde im Lichte der Topistik, Pathoklise und Pathoarchitektonik. J Psychol Neurol 1922;28:1-171.
Hamada S, Ishii T. The Lewy body in the brain of the aged. Adv Neurol Sci 1963;7:184-6.
Hirai S. Ageing of the substantia nigra. Adv Neurol Sci 1968;12:845-9.
Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 1938;48:387-476.

Sorted by citations

Items 501–600 of 1,022

Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease
Lee, W. Y., Yoon, W. T., Shin, H. Y., Jeon, S. H., & Rhee, P. (2008) · Movement Disorders · doi:10.1002/mds.22190 · Cited by 110
Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism
Williams, D. R., Warren, J. D., & Lees, A. J. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.124677 · Cited by 118
Self-citation
Action naming is impaired in Parkinson disease patients
Rodríguez‐Ferreiro, J., Menéndez‐González, M., Ribacoba, R., & Cuetos, F. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.07.007 · Cited by 115
Left hemispheric predominance of nigrostriatal dysfunction in Parkinson’s disease
Scherfler, C., Seppi, K., Mair, K. J., Donnemiller, E., Virgolini, I. J., Wenning, G. K., & Poewe, W. H. (2012) · Brain · doi:10.1093/brain/aws253 · Cited by 115
Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease
Thomas, G. E. C., Zarkali, A., Ryten, M., Shmueli, K., Gil-Martínez, A. L., Leyland, L., McColgan, P., Acosta‐Cabronero, J., Lees, A. J., & Weil, R. S. (2021) · Brain · doi:10.1093/brain/awab084 · Cited by 112
Self-citation
Statistical tools for clinical gait analysis
Duhamel, A., Bourriez, J. L., Devos, P., Krystkowiak, P. C., Destée, A., Derambure, P., & Defebvre, L. (2004) · Gait & Posture · doi:10.1016/j.gaitpost.2003.09.010 · Cited by 115
Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study
Rhee, S. Y., Han, K.-D., Kwon, H., Park, S.-E., Park, Y.-G., Kim, Y.-H., Yoo, S.-J., Rhee, E.-J., & Lee, W.-Y. (2020) · Diabetes Care · doi:10.2337/dc19-0760 · Cited by 109
Relationships between Lewy bodies and pale bodies in Parkinson's disease
Dale, G. E., Probst, A., Luthert, P., Martin, J., Anderton, B. H., & Leigh, P. N. (1992) · Acta Neuropathologica · doi:10.1007/bf00310030 · Cited by 114
Postmortem studies in Parkinson's disease
Hartmann, A. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/ahartmann · Cited by 113
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2021) · Biomolecules · doi:10.3390/biom11050767 · Cited by 115
The Economic Impact of Parkinson???s Disease
Dodel, R. C., Singer, M., Köhne-Volland, R., Szucs, T. D., Rathay, B., Scholz, E., & Oertel, W. H. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814030-00006 · Cited by 113
Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease.
Dujardin, K., Blairy, S., Defebvre, L., Krystkowiak, P. C., Heß, U., Blond, S., & Destée, A. (2004) · PubMed Central · Cited by 114
Functional imaging of the cerebral olfactory system in patients with Parkinson's disease
Westermann, B., Wattendorf, E., Schwerdtfeger, U., Husner, A., Fuhr, P., Gratzl, O., Hummel, T. R., Bilecen, D., & Welge-Lussen, A. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.113860 · Cited by 113
International validation of a behavioral scale in Parkinson's disease without dementia
Rieu, I., Martínez‐Martín, P., Pereira, B., de Chazeron, I., Metman, L. V., Jahanshahi, M., Ardouin, C., Chéreau, I., Brefel‐Courbon, C., Ory‐Magne, F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26223 · Cited by 112
Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease
Ponsen, M. M., Stoffers, D., Wolters, E. C., Booij, J., & Berendse, H. W. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.183715 · Cited by 112
Abnormal excitability of premotor-motor connections in de novo Parkinson's disease
Buhmann, C. (2004) · Brain · doi:10.1093/brain/awh321 · Cited by 115
Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism
Scherfler, C., Göbel, G., Müller, C. F., Nocker, M., Wenning, G. K., Schocke, M. F. H., Poewe, W. H., & Seppi, K. (2016) · Neurology · doi:10.1212/wnl.0000000000002518 · Cited by 112
Detecting the Cognitive Prodrome of Dementia with Lewy Bodies: A Prospective Study of REM Sleep Behavior Disorder
Marchand, D. G., Montplaisir, J. Y., Postuma, R. B., Rahayel, S., & Gagnon, J. (2016) · SLEEP · doi:10.1093/sleep/zsw014 · Cited by 119
Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study
Donadio, V. A., Incensi, A., El‐Agnaf, O. M. A., Rizzo, G., Vaikath, N. N., Sorbo, F. D., Scaglione, C. L. M., Capellari, S., Elia, A. E., Maserati, M. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32588-8 · Cited by 116
Clinical tests for the evaluation of postural instability in patients with parkinson’s disease11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated.
Jeukens‐Visser, M., Marinus, J., Bloem, B. R., Kisjes, H., van den Berg, B. M., & van Hilten, J. J. (2003) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/s0003-9993(03)00348-4 · Cited by 111
Relationship between mild cognitive impairment and falls in older people with and without Parkinson's disease: 1-Year Prospective Cohort Study
Camicioli, R. M., & Majumdar, S. R. (2010) · Gait & Posture · doi:10.1016/j.gaitpost.2010.03.013 · Cited by 110
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease
Foltynie, T., Lewis, S. J. G., Goldberg, T. E., Blackwell, A. D., Kolachana, B. S., Weinberger, D. R., Robbins, T. W., & Barker, R. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0756-5 · Cited by 113
PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results
Noyce, A. J., Bestwick, J., Silveira‐Moriyama, L., Hawkes, C. H., Knowles, C. H., Hardy, J., Giovannoni, G., Nageshwaran, S., Osborne, C., Lees, A. J., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305420 · Cited by 111
Self-citation
Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease
Devos, D. (2004) · Brain · doi:10.1093/brain/awh053 · Cited by 111
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease
Churchyard, A., Mathias, C. J., Boonkongchuen, P., & Lees, A. J. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.2.228 · Cited by 111
Self-citation
Intraindividual variability in neurocognitive speed: A comparison of Parkinson's disease and normal older adults
de Frias, C. M., Dixon, R. A., Fisher, N., & Camicioli, R. M. (2007) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2007.03.022 · Cited by 109
Cognitive training in Parkinson disease
Zimmermann, R., Gschwandtner, U., Benz, N., Hatz, F., Schindler, C., Taub, E., & Fuhr, P. (2014) · Neurology · doi:10.1212/wnl.0000000000000287 · Cited by 109
Skin biopsy for assessment of autonomic denervation in Parkinson’s disease
Dabby, R., Djaldetti, R., Shahmurov, M., Treves, T. A., Gabai, B., Melamed, E., Sadeh, M., & Avinoach, I. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0431-0 · Cited by 108
Impact of recent genetic findings in Parkinson??s disease
Klein, C., & Lohmann-Hedrich, K. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3281e6692b · Cited by 113
GBA Variants Influence Motor and Non-Motor Features of Parkinson’s Disease
Jesús, S., Huertas, I., Bernal‐Bernal, I., Bonilla‐Toribio, M., Cáceres‐Redondo, M. T., Vargas‐González, L., Gómez-Llamas, M., Carrillo, F., Calderón, E. J., Carballo, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167749 · Cited by 108
UCHL‐1 is not a Parkinson's disease susceptibility gene
Healy, D. G., Abou‐Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., Muqit, M. M. K., Foltynie, T., Barker, R. A., Bhatia, K. P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20757 · Cited by 109
Self-citation
Parkinson's disease
Clarke, C. E. (2007) · BMJ · doi:10.1136/bmj.39289.437454.ad · Cited by 109
PINK1 (PARK6) associated Parkinson disease in Ireland
Healy, D. G., Abou‐Sleiman, P. M., Gibson, J. M., Ross, O. A., Jain, S., Gandhi, S., Gosal, D. Y., Muqit, M. M. K., Wood, N. W., & Lynch, T. (2004) · Neurology · doi:10.1212/01.wnl.0000142089.38301.8e · Cited by 109
The frequency and severity of gastrointestinal symptoms in patients with early Parkinson’s disease
Sung, H.-Y., Park, J.-W., & Kim, J.-S. (2014) · Journal of Movement Disorders · doi:10.14802/jmd.14002 · Cited by 106
DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease
Lin, X., Cook, T. J., Zabetian, C. P., Leverenz, J. B., Peskind, E. R., Hu, S., Cain, K. C., Pan, C., Edgar, J. S., Goodlett, D. R., et al. (2012) · Scientific Reports · doi:10.1038/srep00954 · Cited by 110
Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson’s disease
Zhang, J., Rittman, T., Nombela, C., Fois, A. F., Coyle-Gilchrist, I. T. S., Barker, R. A., Hughes, L. E., & Rowe, J. B. (2015) · Brain · doi:10.1093/brain/awv331 · Cited by 109
Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson's disease
Hassan, M., Chaton, L., Benquet, P., Delval, A., Leroy, C., Plomhause, L., Moonen, A. J. H., Duits, A., Leentjens, A. F. G., van Kranen-Mastenbroek, V. H. J. M., et al. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.03.002 · Cited by 107
How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder
Marchand, D. G., Postuma, R. B., Escudier, F., Roy, J. D., Pelletier, A., Montplaisir, J. Y., & Gagnon, J. (2018) · Annals of Neurology · doi:10.1002/ana.25239 · Cited by 114
α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK 2‐linked Parkinson's disease
Garrido, A., Fairfoul, G., TOLOSA, E. S., Martı́, M. J., Green, A. J. E., & the Barcelona LRRK2 Study Group (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.772 · Cited by 108
From genotype to phenotype: A clinical, pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation
Nasreddine, Z. S., Loginov, M., Clark, L. N., Lamarche, J. B., Miller, B. L., Lamontagne, A., Zhukareva, V. A., Lee, V. M. ‐., Wilhelmsen, K. C., & Geschwind, D. H. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199906)45:6 · Cited by 135
The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease
Sung, H. Y., Kim, J., Lee, K., Kim, Y.-I., Song, I., Chung, S., Yang, D., Cho, Y. K., Park, J. M., Lee, I. S., et al. (2010) · Movement Disorders · doi:10.1002/mds.23290 · Cited by 110
Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET
Ikawa, M., Okazawa, H., Kudo, T., Kuriyama, M., Fujibayashi, Y., & Yoneda, M. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.02.016 · Cited by 107
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism
Scherfler, C. (2004) · Brain · doi:10.1093/brain/awh150 · Cited by 108
The Effect of Duloxetine on Primary Pain Symptoms in Parkinson Disease
Djaldetti, R., Yust‐Katz, S., Kolianov, V., Melamed, E., & Dabby, R. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180340319 · Cited by 107
Assessment of psychiatric complications in Parkinson's disease: The SCOPA‐PC
Jeukens‐Visser, M., Verbaan, D., van Rooden, S. M., Stiggelbout, A. M., Marinus, J., & van Hilten, J. J. (2007) · Movement Disorders · doi:10.1002/mds.21696 · Cited by 107
Excessive Daytime Sleepiness in Parkinson’s Disease: Characteristics and Determinants
Poryazova, R., Benninger, D. H., Waldvogel, D., & Bassetti, C. L. (2010) · European Neurology · doi:10.1159/000276402 · Cited by 109
18 F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
Ceravolo, R., Piccini, P. P., Bailey, D. L., Jorga, K. M., Bryson, H., & Brooks, D. J. (2001) · Synapse · doi:10.1002/syn.10034 · Cited by 107
Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France
Tison, F., Dartigues, J.-F., Dubes, L., Zuber, M., Alpérovitch, A., & Henry, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb02689.x · Cited by 107
Subthalamic nucleus stimulation and dysarthria in Parkinson’s disease: a PET study
Pinto, S., Thobois, S., Costes, N., Bars, D. L., Benabid, A., Broussolle, E., Pollak, P., & Gentil, M. (2004) · Brain · doi:10.1093/brain/awh074 · Cited by 112
Significance of Parkinsonian Manifestations in Essential Tremor
Rajput, A. H., Rozdilsky, B., Ang, L. C., & Rajput, A. H. (1993) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710004765x · Cited by 107
Epitopes located in spatially separate domains of each neurofilament subunit are present in parkinson's disease lewy bodies
Hill, W., Lee, V. M. ‐., Hurtig, H. I., Murray, J. M., & Trojanowski, J. Q. (1991) · The Journal of Comparative Neurology · doi:10.1002/cne.903090111 · Cited by 107
Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor
Zach, H., Dirkx, M. F., Pasman, J. W., Bloem, B. R., & Helmich, R. C. G. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12670 · Cited by 110
Benefits of Vitamins in the Treatment of Parkinson’s Disease
Zhao, X., Zhang, M., Li, C., Jiang, X., Su, Y., & Zhang, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9426867 · Cited by 106
Haplotypes and gene expression implicate the MAPT region for Parkinson disease
Tobin, J. E., Latourelle, J. C., Lew, M., Klein, C., Suchowersky, O., Shill, H. A., Golbe, L. I., Mark, M. H., Growdon, J. H., Wooten, G. F., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304051.01650.23 · Cited by 106
The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil
Silveira‐Moriyama, L., Carvalho, M. D. J., Katzenschlager, R., Petrie, A., Ranvaud, R., Barbosa, E. R., & Lees, A. J. (2008) · Movement Disorders · doi:10.1002/mds.22241 · Cited by 106
Self-citation
Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa
Michell, A. W., Xu, Z., Fritz, D., Lewis, S. J. G., Foltynie, T., Williams‐Gray, C. H., Robbins, T. W., Carpenter, R. H. S., & Barker, R. (2006) · Experimental Brain Research · doi:10.1007/s00221-006-0412-z · Cited by 108
Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease
Oeda, T., Umemura, A., Mori, Y., Tomita, S., Kohsaka, M., Park, K., Inoue, K., Fujimura, H., Hasegawa, H., Sugiyama, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.027 · Cited by 106
Retinal Nerve Fiber Layer Thinning in Alzheimer’s Disease
Pillai, J. A., Bermel, R. A., Bonner‐Jackson, A., Rae-Grant, A. D., Fernandez, H. H., Bena, J., Jones, S. E., Ehlers, J. P., & Leverenz, J. B. (2016) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515628053 · Cited by 105
Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?
Merola, A., Romagnolo, A., Rosso, M., Lopez‐Castellanos, J. R., Wissel, B. D., Larkin, S., Bernardini, A., Zibetti, M., Maule, S. V., Lopiano, L., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.09.013 · Cited by 107
A short psychosocial questionnaire for patients with Parkinson's disease
Marinus, J., Jeukens‐Visser, M., Martı́nez-Martı́n, P., van Hilten, J. J., & Stiggelbout, A. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00569-3 · Cited by 106
A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodies
Thomas, A. J., Burn, D. J., Rowan, E. N., Littlewood, E., Newby, J., Cousins, D. A., Pakrasi, S., Richardson, J. L., Sanders, J., & McKeith, I. G. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1381 · Cited by 105
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease
Booij, J., Tissingh, G., Winogrodzka, A., Boer, G. J., Stoof, J. C., Wolters, E. C., & van Royen, E. A. (1997) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf01728311 · Cited by 105
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
(1993) · BMJ · doi:10.1136/bmj.307.6902.469 · Cited by 105
Probable RBD and association with neurodegenerative disease markers: A population‐based study
Mahlknecht, P., Seppi, K., Frauscher, B., Kiechl, S. J., Willeit, J., Stockner, H., Djamshidian, A., Nocker, M., Rastner, V., Defrancesco, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26350 · Cited by 104
The role of high‐intensity focused ultrasound as a symptomatic treatment for Parkinson's disease
Moosa, S., Martínez-Fernández, R., Elias, W., del Álamo, M., Eisenberg, H., & Fishman, P. S. (2019) · Movement Disorders · doi:10.1002/mds.27779 · Cited by 84
MRI Study of Caudate Nucleus Volume in Parkinson’s Disease with and without Dementia with Lewy Bodies and Alzheimer’s Disease
Almeida, O. P., Burton, E. J., McKeith, I. G., Gholkar, A. R., Burn, D. J., & O'Brien, J. T. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000070676 · Cited by 104
Effects of rTMS on Parkinson’s disease: a longitudinal fMRI study
García, N. G., Armony, J. L., Soto, J., Trejo, D., Alegría, M. A., & Drucker-Colı́n, R. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5923-2 · Cited by 106
Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome?
Ondo, W. G., He, Y., Rajasekaran, S., & Le, W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200001)15:1 · Cited by 289
Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Jellinger, K., Logroscino, G., Rizzo, G., Copetti, M., Arcuti, S., Martino, D., & Fontana, A. (2016) · Neurology · doi:10.1212/wnl.0000000000002876 · Cited by 384
Orthostatic hypotension in de novo Parkinson disease
Bonuccelli, U., Lucetti, C., Del Dotto, P., Ceravolo, R., Gambaccini, G., Bernardini, S., Rossi, G., & Piaggesi, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1400 · Cited by 103
Cognitive functioning differentially predicts different dimensions of older drivers’ on-road safety
Aksan, N. S., Anderson, S. W., Dawson, J. D., Uc, E., & Rizzo, M. (2014) · Accident Analysis & Prevention · doi:10.1016/j.aap.2014.12.007 · Cited by 103
Idiopathic REM sleep behavior disorder in the transition to degenerative disease
Postuma, R. B., Gagnon, J., Vendette, M., & Montplaisir, J. Y. (2009) · Movement Disorders · doi:10.1002/mds.22757 · Cited by 100
Awareness of memory deficits in subjective cognitive decline, mild cognitive impairment, Alzheimer's disease and Parkinson's disease
Lehrner, J. P., Kogler, S., Lamm, C., Moser, D., Klug, S., Pußwald, G., Dal‐Bianco, P., Pirker, W., & Auff, E. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214002245 · Cited by 103
Clinical Assessments in Parkinson's Disease
Bhidayasiri, R., & Martínez‐Martín, P. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.01.001 · Cited by 104
Proteomic Profiling of Exosomal Proteins for Blood-based Biomarkers in Parkinson's Disease
Kitamura, Y., Kojima, M., Kurosawa, T., Sasaki, R., Ichihara, S., Hiraku, Y., Tomimoto, H., Murata, M., & Oikawa, S. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.017 · Cited by 103
Characterizing the Genetic Architecture of Parkinson's Disease in Latinos
Loesch, D. P., Horimoto, A. R. V. R., Heilbron, K., Sarihan, E. I., Inca‐Martinez, M., Mason, E., Cornejo‐Olivas, M., Torres, L., Mazzetti, P., Cosentino, C., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26153 · Cited by 96
Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor
Baumann, C. R. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70029-3 · Cited by 103
Low levels of arsenite activates nuclear factor‐κB and activator protein‐1 in immortalized mesencephalic cells
Felix, K., Manna, S. K., WISE, K. C., Barr, J. L., & Ramesh, G. T. (2005) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20062 · Cited by 103
Physiotherapy for Parkinson's disease: a comparison of techniques
Deane, K. H., Jones, D. E., Ellis‐Hill, C., Clarke, C. E., Playford, E. D., & Ben‐Shlomo, Y. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002815 · Cited by 102
Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease
Rodriguez‐Blazquez, C., Frades‐Payo, B., Forjaz, M. J., de Pedro‐Cuesta, J., Martinez‐Martin, P., & on behalf of the Longitudinal Parkinson's Disease Patient Study (Estudio longitudinal de pacientes con enfermedad de Parkinson ‐ELEP) Group (2009) · Movement Disorders · doi:10.1002/mds.22321 · Cited by 97
Functional neurological disorders in Parkinson disease
Wissel, B. D., Dwivedi, A. K., Merola, A., Chin, D., Jacob, C., Duker, A. P., Vaughan, J. E., Lovera, L., LaFaver, K., Levy, A., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317378 · Cited by 106
Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion
Vitale, C., Marcelli, V., Furia, T., Santangelo, G., Cozzolino, A., Longo, K., Allocca, R., Amboni, M., Marciano, E., & Barone, P. (2011) · Movement Disorders · doi:10.1002/mds.23657 · Cited by 102
Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial.
Clarke, C., Patel, S., Ives, N., Rick, C., Dowling, F., Woolley, R., Wheatley, K., Walker, M., & Sackley, C. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4452 · Cited by 95
DJ‐1 deficiency impairs autophagy and reduces alpha‐synuclein phagocytosis by microglia
Nash, Y., Schmukler, E., Trudler, D., Pinkas‐Kramarski, R., & Frenkel, D. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14222 · Cited by 100
Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study
Goerendt, I. K. (2003) · Brain · doi:10.1093/brain/awg035 · Cited by 100
EXHAUSTIVE, ONE-YEAR FOLLOW-UP OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION IN A LARGE, SINGLE-CENTER COHORT OF PARKINSONIAN PATIENTS
Tir, M., Devos, D., Blond, S., Touzet, G., Reyns, N., Duhamel, A., Cottencin, O., Dujardin, K., Cassim, F., Destée, A., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000285347.50028.b9 · Cited by 101
γ‐Synuclein and the progression of cancer
Ahmad, M., Attoub, S., Singh, M. N., Martin, F. L., & El‐Agnaf, O. M. A. (2007) · The FASEB Journal · doi:10.1096/fj.07-8379rev · Cited by 103
Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging
Burton, E. J., McKeith, I. G., Burn, D. J., & O'Brien, J. T. (2005) · Movement Disorders · doi:10.1002/mds.20652 · Cited by 102
Repetitive speech phenomena in Parkinson's disease
Benke, T. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.319 · Cited by 102
Voice and choral singing treatment: a new approach for speech and voice disorders in Parkinson's disease.
Benedetto, P. D., Cavazzon, M., Mondolo, F., Rugiu, G., Peratoner, A., & Biasutti, E. (2009) · PubMed · Cited by 102
When did Ray Kennedy's Parkinson's disease begin?
Lees, A. J. (1992) · Movement Disorders · doi:10.1002/mds.870070203 · Cited by 102
Self-citation
Neuronal inclusions of Parkinson's disease
Gibb, W. R. G., Scott, T., & Lees, A. J. (1991) · Movement Disorders · doi:10.1002/mds.870060103 · Cited by 102
Self-citation
Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study.
A, T., Yang, K., Sung, J. H., & Frey, W. H. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.16 · Cited by 102
Pergolide monotherapy in the treatment of early PD
Barone, P., Bravi, D., Bermejo‐Pareja, F., Marconi, R., Kulisevsky, J., Malagù, S., Weiser, R., Rost, N. S., & the Pergolide Monotherapy Study Group (1999) · Neurology · doi:10.1212/wnl.53.3.573 · Cited by 102
The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease
Mata, I. F., Jang, Y., Kim, C., Hanna, D. S., Dorschner, M. O., Samii, A., Agarwal, P., Roberts, J. W., Klepitskaya, O., Shprecher, D., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0045-4 · Cited by 101
Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild
Müller, B., Larsen, J. P., Wentzel‐Larsen, T., SKEIE, G. O., Tysnes, O., & for The Parkwest Study Group (2010) · Movement Disorders · doi:10.1002/mds.23387 · Cited by 101
Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia
Santangelo, G., Vitale, C., Trojano, L., Longo, K., Cozzolino, A., Grossi, D., & Barone, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0146-5 · Cited by 101
Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease
Kim, H. J., Kim, S. J., Kim, H. S., Choi, C. G., Kim, N., Han, S., Jang, E. H., Chung, S. J., & Lee, C. S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.050 · Cited by 101
Nigrostriatal dopamine transporter availability in early Parkinson's disease
Fazio, P., Svenningsson, P., Cselényi, Z., Halldin, C., Farde, L., & Varrone, A. (2018) · Movement Disorders · doi:10.1002/mds.27316 · Cited by 101
Postural sway and falls in Parkinson's disease: A regression approach
Matinolli, M., Korpelainen, J. T., Korpelainen, R., Sotaniemi, K. A., Virranniemi, M., & Myllylä, V. V. (2007) · Movement Disorders · doi:10.1002/mds.21633 · Cited by 101

Authors: Gibb, W. R., & Lees, A. J.
ORCID: Gibb, W R
Lees, A J
Venue: Journal of Neurology, Neurosurgery & Psychiatry
Publisher: BMJ
Published: 1988-06-01
Volume: 51
Issue: 6
Pages: 745-752
ISSN: 0022-3050 (ISSN-L)
DOI: 10.1136/jnnp.51.6.745
PMC: PMC1033142
OpenAlex: W2132881915
Semantic Scholar: 354cd1cf28ad23a8038bb3c576ff7791b3c74543
Cited by: 3,481
References: 39
Citations by year: 2026: 78 · 2025: 130 · 2024: 152 · 2023: 143 · 2022: 131 · 2021: 158 · 2020: 164 · 2019: 152 · 2018: 138 · 2017: 156 · 2016: 163 · 2015: 115 · 2014: 149 · 2013: 123 · 2012: 138
FWCI: 3.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
PubMed Central (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: Lewy bodies, Parkinson's disease, pathogenesis, neurofilaments, substantia nigra, incidental Lewy body disease, age-related prevalence, neuronal loss
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Brain, Brain Damage, Chronic, Inclusion Bodies, Child, Humans, Middle Aged, Nerve Degeneration, Parkinson Disease, Substantia Nigra

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks